Oxycodone and Acetaminophen side effects: what 12,035 FDA adverse event reports show
Drug class
Not stated in label
Label matched
Oxycodone (Oxycodone Hydrochloride)
Who reports
12,035 reports · 70% serious · 1,613 with death outcome · 63% female
Used for
Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdo.
What it is
Oxycodone HCl tablets, USP contains oxycodone, an opioid agonist.
Boxed warning
SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,155 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Grip strength | 101 | 165.4 127.4–214.7ROR 165.6 · calibrated p 4e-9 ✓ | 91.3 EB05 77.3 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | serious n=38 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Dependence | 18,814 | 109.5 107.7–111.3ROR 135.2 · calibrated p 1e-8 ✓ | 72.3 EB05 71.4 · IC025 +6.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 7.5 · ♀ 39% (drug 63%) · 100% consumer | no trial arm names this drug |
| Swollen joint count | 51 | 55.7 40.9–75.8ROR 55.7 · calibrated p 1e-5 ✓ | 43.5 EB05 34.4 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=29 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Drug withdrawal syndrome neonatal | 2,919 | 51.7 49.6–53.8ROR 53.2 · calibrated p 9e-6 ✓ | 41.6 EB05 40.4 · IC025 +5.3 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 35.5 · ♀ 43% (drug 63%) · 100% consumer | no trial arm names this drug |
| Vision abnormal neonatal | 75 | 45.8 35.7–58.8ROR 45.9 · calibrated p 3e-5 ✓ | 37.5 EB05 30.9 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=71 · 100% consumer | no trial arm names this drug |
| Learning disorder | 395 | 41.1 36.9–45.8ROR 41.3 · calibrated p 4e-5 ✓ | 34.5 EB05 31.7 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Opisthotonus | 127 | 40.1 33.2–48.5ROR 40.1 · calibrated p 6e-5 ✓ | 33.7 EB05 29.0 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Poor feeding infant | 148 | 34.2 28.7–40.7ROR 34.3 · calibrated p 1e-4 ✓ | 29.4 EB05 25.7 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Lupus vulgaris | 159 | 32.8 27.8–38.8ROR 32.9 · calibrated p 2e-4 ✓ | 28.4 EB05 24.9 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=100 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Speech disorder developmental | 382 | 32.5 29.2–36.2ROR 32.6 · calibrated p 2e-4 ✓ | 28.2 EB05 25.9 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Deep vein thrombosis postoperative | 250 | 31.1 27.2–35.5ROR 31.2 · calibrated p 2e-4 ✓ | 27.1 EB05 24.4 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=184 · ♀ 100% (drug 63%) · 96% clinician | no trial arm names this drug |
| Drug diversion | 653 | 27.4 25.2–29.7ROR 27.6 · calibrated p 4e-4 ✓ | 24.3 EB05 22.8 · IC025 +4.5 3/3 methods agree | Reporting / coding artifact | serious n=20 · 75% consumer | no trial arm names this drug |
| X-ray abnormal | 189 | 25.2 21.7–29.3ROR 25.2 · calibrated p 7e-4 ✓ | 22.5 EB05 20.0 · IC025 +4.2 3/3 methods agree | Lab value / disease marker | serious n=130 · ♀ 100% (drug 63%) · 95% clinician | no trial arm names this drug |
| Ill-defined disorder | 6,428 | 25.2 24.5–25.8ROR 26.8 · calibrated p 5e-4 ✓ | 22.6 EB05 22.1 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | age-adj. PRR 26.3 · serious PRR 22.2 · ♀ 86% (drug 63%) | no trial arm names this drug |
| Adjustment disorder with depressed mood | 203 | 23.8 20.6–27.5ROR 23.9 · calibrated p 9e-4 ✓ | 21.4 EB05 19.1 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=145 · ♀ 100% (drug 63%) · 96% clinician | no trial arm names this drug |
| Developmental delay | 900 | 23.3 21.8–25.0ROR 23.6 · calibrated p 9e-4 ✓ | 21.1 EB05 20.0 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious PRR 55.3 · ♀ 42% (drug 63%) · 100% consumer | no trial arm names this drug |
| Sleep disorder due to general medical condition, insomnia type | 627 | 22.9 21.1–24.9ROR 23.1 · calibrated p 0.001 ✓ | 20.8 EB05 19.4 · IC025 +4.2 3/3 methods agree | Labeled (related wording) related wording | serious n=520 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| Polysubstance abuse | 60 | 21.8 16.7–28.5ROR 21.8 · calibrated p 0.002 ✓ | 19.8 EB05 15.9 · IC025 +3.7 3/3 methods agree | Reporting / coding artifact | – | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 62 | 21.8 16.8–28.3ROR 21.8 · calibrated p 0.002 ✓ | 19.7 EB05 15.9 · IC025 +3.7 3/3 methods agree | Lab value / disease marker | serious n=49 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Subcutaneous drug absorption impaired | 50 | 21.5 16.1–28.7ROR 21.5 · calibrated p 0.002 ✓ | 19.4 EB05 15.3 · IC025 +3.6 3/3 methods agree | Labeled (related wording) related wording | serious n=44 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Muscle injury | 738 | 21.0 19.5–22.7ROR 21.2 · calibrated p 0.002 ✓ | 19.2 EB05 18.0 · IC025 +4.1 3/3 methods agree | Labeled (related wording) related wording | serious PRR 117.2 · ♀ 100% (drug 63%) · 94% clinician | no trial arm names this drug |
| C-reactive protein | 81 | 20.8 16.6–26.2ROR 20.8 · calibrated p 0.002 ✓ | 19.0 EB05 15.7 · IC025 +3.7 3/3 methods agree | Lab value / disease marker | serious n=63 · ♀ 100% (drug 63%) · 95% clinician | no trial arm names this drug |
| Porphyria acute | 123 | 20.8 17.3–25.0ROR 20.8 · calibrated p 0.002 ✓ | 19.0 EB05 16.3 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=77 · ♀ 100% (drug 63%) · 92% clinician | no trial arm names this drug |
| Dislocation of vertebra | 198 | 20.8 18.0–24.0ROR 20.8 · calibrated p 0.002 ✓ | 19.0 EB05 16.8 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=137 · ♀ 100% (drug 63%) · 94% clinician | no trial arm names this drug |
| Duodenal ulcer perforation | 647 | 20.6 19.0–22.3ROR 20.7 · calibrated p 0.002 ✓ | 18.8 EB05 17.6 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious PRR 105.0 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody positive | 615 | 20.1 18.5–21.9ROR 20.3 · calibrated p 0.002 ✓ | 18.5 EB05 17.3 · IC025 +4.1 3/3 methods agree | Lab value / disease marker | serious PRR 104.5 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| Facet joint syndrome | 272 | 20.1 17.7–22.7ROR 20.1 · calibrated p 0.002 ✓ | 18.4 EB05 16.6 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=162 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| Learning disability | 441 | 18.9 17.2–20.9ROR 19.0 · calibrated p 0.003 ✓ | 17.4 EB05 16.1 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=339 · ♀ 40% (drug 63%) · 100% consumer | no trial arm names this drug |
| Swollen joint count increased | 252 | 18.7 16.4–21.3ROR 18.7 · calibrated p 0.003 ✓ | 17.2 EB05 15.5 · IC025 +3.9 3/3 methods agree | Lab value / disease marker | serious n=200 · ♀ 100% (drug 63%) · 96% clinician | no trial arm names this drug |
| Retinitis | 133 | 18.4 15.4–22.0ROR 18.4 · calibrated p 0.003 ✓ | 17.0 EB05 14.7 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=76 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Folliculitis | 773 | 17.2 16.0–18.5ROR 17.3 · calibrated p 0.004 ✓ | 16.0 EB05 15.0 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious PRR 103.4 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
| Attention deficit hyperactivity disorder | 292 | 16.1 –ROR 16.1 · – | – | Not in label — unassessed | serious n=7 | no trial arm names this drug |
| Withdrawal syndrome | 2,893 | 15.6 15.1–16.2ROR 16.1 · calibrated p 0.005 ✓ | 14.6 EB05 14.2 · IC025 +3.8 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 3.7 · serious PRR 8.4 · 87% consumer | no trial arm names this drug |
| Overdose | 14,261 | 15.0 14.7–15.2ROR 17.4 · calibrated p 0.004 ✓ | 14.0 EB05 13.9 · IC025 +3.8 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 2.9 · serious PRR 3.1 | no trial arm names this drug |
| Rheumatic fever | 286 | 14.9 13.2–16.8ROR 14.9 · calibrated p 0.007 ✓ | 13.9 EB05 12.6 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=217 · ♀ 100% (drug 63%) · 94% clinician | no trial arm names this drug |
| Helicobacter infection | 666 | 14.9 13.7–16.1ROR 15.0 · calibrated p 0.007 ✓ | 13.9 EB05 13.1 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious PRR 82.1 · ♀ 100% (drug 63%) · 94% clinician | no trial arm names this drug |
| Toxicity to various agents | 9,580 | 12.9 12.6–13.1ROR 14.2 · calibrated p 0.009 ✓ | 12.2 EB05 12.0 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.8 · serious PRR 1.5 | no trial arm names this drug |
| Primary sequestrum | 49 | 12.0 9.0–16.0ROR 12.0 · calibrated p 0.019 ✓ | 11.1 EB05 8.6 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Hand deformity | 686 | 11.8 10.9–12.7ROR 11.8 · calibrated p 0.018 ✓ | 11.2 EB05 10.5 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious PRR 66.8 · ♀ 99% (drug 63%) · 93% clinician | no trial arm names this drug |
| Peripheral venous disease | 208 | 11.7 10.2–13.4ROR 11.7 · calibrated p 0.019 ✓ | 11.0 EB05 9.8 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious n=151 · ♀ 100% (drug 63%) · 93% clinician | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Dependence / withdrawal | 1,117 | 6.66.2–7.0 | signal |
| Liver injury | 740 | 4.34.0–4.6 | signal |
| Depression | 615 | 3.83.5–4.1 | signal |
| Serious infection | 1,445 | 3.33.1–3.4 | signal |
| Interstitial lung disease | 159 | 2.92.5–3.4 | signal |
| Pancreatitis | 129 | 2.82.3–3.3 | signal |
| Suicidality | 364 | 2.62.3–2.9 | signal |
| Fall / fracture | 486 | 2.22.0–2.4 | signal |
| Hyperglycaemia / diabetes | 420 | 2.11.9–2.3 | raised |
| Kidney injury | 505 | 1.91.8–2.1 | raised |
| Gi bleeding | 202 | 1.91.7–2.2 | raised |
| Rhabdomyolysis / myopathy | 83 | 1.81.4–2.2 | raised |
| Thrombocytopenia | 206 | 1.61.4–1.9 | raised |
| Anaemia | 237 | 1.41.2–1.6 | raised |
| Opportunistic infection | 106 | 1.41.1–1.6 | raised |
| Venous thromboembolism | 168 | 1.41.2–1.6 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Dependence | 18,814 | 109.5 107.7–111.3ROR 135.2 · calibrated p 1e-8 ✓ | 72.3 EB05 71.4 · IC025 +6.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 7.5 · ♀ 39% (drug 63%) · 100% consumer | no trial arm names this drug |
| Death | 16,288 | 4.1 4.0–4.2ROR 4.7 · calibrated p 0.268 | 4.0 EB05 4.0 · IC025 +2.0 3/3 methods agree | Outcome field, not a reaction boxed warning mentions mortality | age-adj. PRR 1.4 · serious PRR 0.9 | no trial arm names this drug |
| Overdose | 14,261 | 15.0 14.7–15.2ROR 17.4 · calibrated p 0.004 ✓ | 14.0 EB05 13.9 · IC025 +3.8 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 2.9 · serious PRR 3.1 | no trial arm names this drug |
| Toxicity to various agents | 9,580 | 12.9 12.6–13.1ROR 14.2 · calibrated p 0.009 ✓ | 12.2 EB05 12.0 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.8 · serious PRR 1.5 | no trial arm names this drug |
| Ill-defined disorder | 6,428 | 25.2 24.5–25.8ROR 26.8 · calibrated p 5e-4 ✓ | 22.6 EB05 22.1 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | age-adj. PRR 26.3 · serious PRR 22.2 · ♀ 86% (drug 63%) | no trial arm names this drug |
| Pain | 5,995 | 2.1 2.0–2.1ROR 2.2 · calibrated p 0.971 | 2.1 EB05 2.0 · IC025 +1.0 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 4.6 · serious PRR 4.7 | no trial arm names this drug |
| Nausea | 4,702 | 1.3 1.2–1.3ROR 1.3 · calibrated p 0.499 | 1.3 EB05 1.2 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 2.1 · serious PRR 2.2 | no trial arm names this drug |
| Drug dependence | 4,589 | 6.2 6.0–6.3ROR 6.4 · calibrated p 0.125 | 6.0 EB05 5.9 · IC025 +2.5 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 5.7 · serious PRR 6.3 · ♀ 39% (drug 63%) · 96% consumer | no trial arm names this drug |
| Fatigue (tiredness) | 4,572 | 1.3 1.2–1.3ROR 1.3 · calibrated p 0.488 | 1.3 EB05 1.2 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 3.1 · serious PRR 4.0 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 4,500 | 0.7 0.7–0.7ROR 0.7 · calibrated p 0.138 | 0.7 EB05 0.7 · IC025 -0.5 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 2.3 · serious PRR 2.6 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 3,329 | 1.3 1.2–1.3ROR 1.3 · calibrated p 0.485 | 1.3 EB05 1.2 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 3.1 · serious PRR 3.3 · ♀ 83% (drug 63%) | no trial arm names this drug |
| Diarrhoea (diarrhea) | 3,318 | 1.1 1.1–1.1ROR 1.1 · calibrated p 0.376 | 1.1 EB05 1.1 · IC025 +0.1 | Labeled adverse reaction exact term | age-adj. PRR 2.2 · serious PRR 2.4 | no trial arm names this drug |
| Headache | 3,273 | 1.1 1.1–1.2ROR 1.1 · calibrated p 0.386 | 1.1 EB05 1.1 · IC025 +0.1 | Labeled adverse reaction exact term | age-adj. PRR 2.4 · serious PRR 3.1 · ♀ 85% (drug 63%) | no trial arm names this drug |
| Vomiting | 3,051 | 1.4 1.3–1.4ROR 1.4 · calibrated p 0.578 | 1.4 EB05 1.3 · IC025 +0.4 | Labeled adverse reaction exact term | age-adj. PRR 2.6 · serious PRR 2.5 | no trial arm names this drug |
| Anxiety | 3,018 | 2.3 2.2–2.4ROR 2.3 · calibrated p 0.897 | 2.3 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 3.8 · serious PRR 4.7 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Grip strength — n=101, PRR 165.4
- Swollen joint count — n=51, PRR 55.7
- Vision abnormal neonatal — n=75, PRR 45.8
- Learning disorder — n=395, PRR 41.1
- Opisthotonus — n=127, PRR 40.1
- Poor feeding infant — n=148, PRR 34.2
- Lupus vulgaris — n=159, PRR 32.8
- Speech disorder developmental — n=382, PRR 32.5
- Deep vein thrombosis postoperative — n=250, PRR 31.1
- Ill-defined disorder — n=6,428, PRR 25.2
✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone ↔ Drug dependence / withdrawal syndrome.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Oxycodone and Acetaminophen?
In FDA FAERS, the most frequently co-reported reaction terms for Oxycodone and Acetaminophen are dependence, toxicity to various agents, ill-defined disorder, pain, nausea, fatigue. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Oxycodone and Acetaminophen have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.
Do FAERS signals prove that Oxycodone and Acetaminophen causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 6b6db42b-9821-4aa6-8566-297037d84079, effective 20260723; matched on
openfda.generic_name.exact:"OXYCODONE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,195 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
OXYCODONE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.